Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Protalix BioTherapeutics's Enterprise Value is $148.35 Mil.
Protalix BioTherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $13.00 Mil. Therefore, Protalix BioTherapeutics's EV-to-FCF for today is 11.41.
The historical rank and industry rank for Protalix BioTherapeutics's EV-to-FCF or its related term are showing as below:
PLX'
s EV-to-FCF Range Over the Past 10 Years
Min: -128.25 Med: -5.56 Max: 34
Current: 11.41
During the past 13 years, the highest EV-to-FCF of Protalix BioTherapeutics was 34.00. The lowest was -128.25. And the median was -5.56.
PLX's EV-to-FCF is ranked better than 55.69% of 343
companies
in the Biotechnology industry
Industry Median: 14.7
vs PLX: 11.41
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Protalix BioTherapeutics's PE Ratio (TTM) for today is calculated as:
Protalix BioTherapeutics's share price for today is $2.37.
Protalix BioTherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.180.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Protalix BioTherapeutics EV-to-FCF Related Terms
Protalix BioTherapeutics EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Protalix BioTherapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protalix BioTherapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Protalix BioTherapeutics's EV-to-FCF falls into.
Protalix BioTherapeutics's current Enterprise Value is $148.35 Mil.
Protalix BioTherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protalix BioTherapeutics (PLX) has a EV-to-FCF of 11.41 as of Jul. 26, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Protalix BioTherapeutics and its competitors. According to the industry distribution chart, Protalix BioTherapeutics ranks #152 out of 343 companies in the Biotechnology industry, placing it in the top 44.3%.
Is Protalix BioTherapeutics' EV-to-FCF too high?
Protalix BioTherapeutics' current EV-to-FCF is 11.41. The Biotechnology industry median EV-to-FCF is 14.70. Protalix BioTherapeutics' value of 11.41 is 22.4% below this industry median. Based on the distribution chart, Protalix BioTherapeutics ranks #152 out of 343 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Protalix BioTherapeutics has a GF Score™ of 54/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Protalix BioTherapeutics' EV-to-FCF compare to OKUR and ANTX?
According to the Biotechnology industry distribution chart, Protalix BioTherapeutics ranks #152 out of 343 companies for EV-to-FCF. This puts Protalix BioTherapeutics in the upper half of its industry. The industry median EV-to-FCF is 14.70. Protalix BioTherapeutics' value of 11.41 is 22.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.70, based on 343 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protalix BioTherapeutics's current EV-to-FCF of 11.41 is 22.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Protalix BioTherapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protalix BioTherapeutics's current EV-to-FCF is 11.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protalix BioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protalix BioTherapeutics (PLX) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.12, compared to a current price of $2.37 — trading 11.8% above its estimated fair value. The current EV-to-FCF is 11.41 and 22.4% below the Biotechnology industry median of 14.70. Protalix BioTherapeutics' overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Protalix BioTherapeutics (PLX), the current EV-to-FCF is 11.41 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protalix BioTherapeutics (PLX) Overvalued in 2026?
Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued.
The current stock price of $2.37 is trading 11.8% above its estimated GF Value™ of $2.12.
GuruFocus considers Protalix BioTherapeutics to be Modestly Overvalued.
Key valuation signals for PLX:
EV-to-FCF: 11.41
GF Value™: $2.12 vs. price of $2.37 (11.8% above fair value)
Industry Position: 22.4% below the Biotechnology median (#152 of 343)
No single metric tells the full story. See the PLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
54GF Score
Get the complete analysis for PLX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLX has been successfully added to your 
